Viral drug susceptibility testing

Details Viral drug susceptibility testing Viral drug susceptibility testing

2011-01-25

2011-01-25

Peng, Bo (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

C435S239000, C424S207100

Reexamination Certificate

active

07875422

ABSTRACT:
A method of testing phenotypic drug susceptibility in an enveloped virus-infected mammalian individual by testing on an enzyme packed into an enveloped virus, such as HIV, recovered from a biological sample, such as blood or plasma, from said individual is described. The method comprises the steps of a) adding an enzyme inactivating agent to the sample for inactivating polymerase activity other than that present in the enveloped virion, b) removing the enzyme inactivating agent, enzyme activity blocking antibodies, endogenous enzyme activity inhibitors and antiviral drugs, c) lysing the virus particle to release the enzyme, d) recovering the concentrated purified viral enzyme, such as a HIV reverse transcriptase (RT), resulting from c) and determining the drug sensitivity profile of the individual from the recovered enzyme by using sensitive enzyme assays. The drug sensitivity profile may be used for selecting drug treatment therapy. A commercial package is included.

REFERENCES:
patent: 4707439 (1987-11-01), Seto et al.
patent: 9428115 (1994-08-01), None
patent: 9732995 (1997-12-01), None
patent: WO 01/01129 (2001-01-01), None
patent: 0175147 (2001-11-01), None
Vazquez-Rosales et al. Rapid Screening of Phenotypic Resistance to Nevirapine by Direct Analysis of HIV Type 1 Reverse Transcriptase Activity in Plasma, Nov. 13, 1999, Aids Research and Human Retroviruses, vol. 15, pp. 1191-1200.
Rytting et al., Colorimetric Capture Assay for Human-Immunodeficiency-Virus-1 Reverse Transcriptase Activity, 1999, Biotechnology and Applied Biochemistry, vol. 29, pp. 241-250.
Ventura et al., Effect of Nucleoside Analogs and Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase on Cell-Free Virions, 1999, Archives of Virology, vol. 144, pp. 513-523.
Woolf et al., Column-Switching High-Performance Liquid Chromatographic Determination of a 2-Pyridinnone-Based Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Reverse Transcriptase Inhibitor in Human Plasma, Pharmaceutical Research, 1993, vol. 10, No. 1, pp. 56-60.
Hertogs et al., Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS, Jun. 2000, vol. 14, No. 9, pp. 1203-1210.
Hertogs et al., A Rapid Method for Simutaneous Detection of Phenotypic Resistanve to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy, Feb. 1998, vol. 42, No. 2, pp. 269-276.
Petropoulos et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy, Apr. 2000, vol. 44, No. 4, pp. 920-928.
Davis et al. Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. Journal of Virology, Feb. 1999, vol. 73, No. 2, pp. 1156-1164.
Zahler et al. A specific and sensitive assay for disulfides. The Journal of Biological Chemistry, Feb. 1968, vol. 243, No. 4, pp. 716-719.
Chavan et al. Archives of Biochemistry and Biophysics, Dec. 1, 1995, vol. 324, No. 1, pp. 143-152.
Kellam et al. Antimicrobial Agents and Chemotherapy, 1994, vol. 38, No. 1, pp. 23-30.
Ekstrand et al. Biotechnological Applied Biochemistry, 1996, vol. 23, No. 2, pp. 95-105.
Tummino et al. Antimicrobial Agents and Chemotherapy, Feb. 1997, vol. 41, No. 2, pp. 394-400.
Bio Techniques, vol. 20, Feb. 1996, Raimond Lugert et al.: “Short Technical Reports: Specific Suppression of False-Positive Signals in the Product-Enhanced Reverse Transcriptase Assay”, pp. 210-217.
National Library of Medicine (NLM), file Medline, Medline accession No. 10480632, Vazquez-Rosales G. et al., “Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma”; & AIDS research and human retroviruses, vol. 15, No. 13, Sep. 1, 1999, pp. 1191-1200.
Dev. Biol. Stand. Basel Karger, vol. 88, 1996, R.A. Metz et al., “The Reverse Transcriptase Assay: Problems and Practical Solutions”, pp. 167-176.

Affiliated with

Also associated with

Rating

Viral drug susceptibility testing does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral drug susceptibility testing, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral drug susceptibility testing will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2698829